ZTS Q3 2023 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena

ZTSZoetis Inc.

$54B

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.2B+7.4% YoY

Gross Profit

$1.5B68.6% margin

Operating Income

$798M37.1% margin

Net Income

$596M27.7% margin

EPS (Diluted)

$1.29

QoQ Revenue Growth

-1.3%

Cash Flow

Operating Cash Flow

$724M

Free Cash Flow

$579M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$14.1B

Total Liabilities

$9.0B

Stockholders' Equity

$5.1B

Cash & Equivalents

$1.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.2B	$2.0B	+7.4%
Gross Profit	$1.5B	$1.4B	+8.6%
Operating Income	$798M	$723M	+10.4%
Net Income	$596M	$529M	+12.7%

Revenue Segments

Dogs and Cats

$1.4B64%

Cattle

$374M18%

Swine

$129M6%

Poultry

$127M6%

Horses

$60M3%

Fish

$57M3%

Geographic Segments

United States Segment

$1.2B55%

International Segment

$956M45%